MoonLake Immunotherapeutics
General ticker "MLTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.8B (TTM average)
MoonLake Immunotherapeutics does not follow the US Stock Market performance with the rate: -28.2%.
Estimated limits based on current volatility of 3.3%: low 18.26$, high 19.50$
Factors to consider:
- Total employees count: 100 (+100.0%) as of 2024
- Top business risk factors: Dependence on SLK, Market competition, Product safety concerns, Capital raising, Geopolitical risks
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.81$, 20.72$]
- 2026-12-31 to 2027-12-31 estimated range: [5.40$, 15.68$]
Financial Metrics affecting the MLTX estimates:
- Negative: with PPE of -3.9 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 23.22 > -0.60
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0.83 <= 3.31
- Negative: negative Industry operating income (median)
- Negative: negative Industry operating cash flow (median)
Short-term MLTX quotes
Long-term MLTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $54.12MM | $143.09MM | $244.83MM |
| Operating Income | $-54.12MM | $-143.09MM | $-244.83MM |
| Non-Operating Income | $10.14MM | $22.13MM | $15.12MM |
| Interest Expense | $0.00MM | $0.00MM | $7.25MM |
| R&D Expense | $31.80MM | $112.77MM | $202.86MM |
| Income(Loss) | $-43.98MM | $-120.96MM | $-229.71MM |
| Taxes | $-0.09MM | $0.28MM | $0.61MM |
| Net Income(Loss)* | $-36.01MM | $-118.94MM | $-227.32MM |
| Stockholders Equity | $495.68MM | $446.82MM | $304.48MM |
| Assets | $526.54MM | $477.93MM | $424.43MM |
| Operating Cash Flow | $-42.78MM | $-116.59MM | $-196.01MM |
| Capital expenditure | $0.28MM | $0.52MM | $0.04MM |
| Investing Cash Flow | $-25.18MM | $-205.60MM | $202.99MM |
| Financing Cash Flow | $479.70MM | $51.31MM | $146.00MM |
| Earnings Per Share** | $-0.73 | $-1.89 | $-3.53 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.